Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moasser, M. M.
Right arrow Articles by Rosen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moasser, M. M.
Right arrow Articles by Rosen, N.
[Cancer Research 61, 7184-7188, October 1, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells1

Mark M. Moasser2, Andrea Basso, Steven D. Averbuch and Neal Rosen

Department of Medicine [M. M. M., N. R.] and Program in Cell Biology [N. R.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Program in Pharmacology, Weill Graduate School of Medical Sciences of Cornell University, New York, New York 10021 [A. B.]; and AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 and Macclesfield, Cheshire, United Kingdom SK10 4TG [S. D. A.]

The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors and provides a new target for anticancer drug development. ZD1839 ("Iressa"), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials. However, because it remains unclear which tumor types are the best targets for treatment with this agent, the molecular characteristics that correlate with tumor sensitivity to ZD1839 have been studied. In a panel of human breast cancer and other epithelial tumor cell lines, HER2-overexpressing tumors were particularly sensitive to ZD1839. Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with phosphatidylinositol 3-kinase, and down-regulation of Akt activity. These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family tyrosine kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. T. Lee-Hoeflich, L. Crocker, E. Yao, T. Pham, X. Munroe, K. P. Hoeflich, M. X. Sliwkowski, and H. M. Stern
A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
Cancer Res., July 15, 2008; 68(14): 5878 - 5887.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al.
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4484 - 4490.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. J. Gonzales, K. E. Hook, I. W. Althaus, P. A. Ellis, E. Trachet, A. M. Delaney, P. J. Harvey, T. A. Ellis, D. M. Amato, J. M. Nelson, et al.
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Mol. Cancer Ther., July 1, 2008; 7(7): 1880 - 1889.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Kinkade, P. Dasgupta, A. Carie, D. Pernazza, M. Carless, S. Pillai, N. Lawrence, S. M. Sebti, and S. Chellappan
A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice
Cancer Res., May 15, 2008; 68(10): 3810 - 3818.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo
Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu
Cancer Res., July 15, 2007; 67(14): 6825 - 6843.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Cappuzzo, C. Ligorio, P. A. Janne, L. Toschi, E. Rossi, R. Trisolini, D. Paioli, A. J. Holmes, E. Magrini, G. Finocchiaro, et al.
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial
J. Clin. Oncol., June 1, 2007; 25(16): 2248 - 2255.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
S. Bouyain and D. J. Leahy
Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3
Protein Sci., April 1, 2007; 16(4): 654 - 661.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Santiago-Josefat, C. Esselens, J. J. Bech-Serra, and J. Arribas
Post-transcriptional Up-regulation of ADAM17 upon Epidermal Growth Factor Receptor Activation and in Breast Tumors
J. Biol. Chem., March 16, 2007; 282(11): 8325 - 8331.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Schaefer, L. Shao, K. Totpal, and R. W. Akita
Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression
Cancer Res., February 1, 2007; 67(3): 1228 - 1238.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, S. Barr, S. Thompson, R. Sennello, D. Young, K. K. Iwata, N. W. Gibson, P. Cagnoni, and J. D. Haley
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Mol. Cancer Ther., February 1, 2007; 6(2): 532 - 541.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Okano, T. Kondo, K. Fujii, T. Nishimura, T. Takano, Y. Ohe, K. Tsuta, Y. Matsuno, A. Gemma, H. Kato, et al.
Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Clin. Cancer Res., February 1, 2007; 13(3): 799 - 805.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Toschi and F. Cappuzzo
Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, February 1, 2007; 12(2): 211 - 220.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al.
Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis
Cancer Res., January 15, 2007; 67(2): 827 - 835.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Ono and M. Kuwano
Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J. D. Haley, K. K. Iwata, N. W. Gibson, and G. Griffin
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Mol. Cancer Ther., November 1, 2006; 5(11): 2676 - 2684.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Lanza-Jacoby, R. Burd, F. E. Rosato Jr., K. McGuire, J. Little, N. Nougbilly, and S. Miller
Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6161 - 6169.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Rojo, J. Tabernero, J. Albanell, E. Van Cutsem, A. Ohtsu, T. Doi, W. Koizumi, K. Shirao, H. Takiuchi, S. R. Cajal, et al.
Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma
J. Clin. Oncol., September 10, 2006; 24(26): 4309 - 4316.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Massarweh, C. K. Osborne, S. Jiang, A. E. Wakeling, M. Rimawi, S. K. Mohsin, S. Hilsenbeck, and R. Schiff
Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer
Cancer Res., August 15, 2006; 66(16): 8266 - 8273.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, J. D. Haley, N. W. Gibson, P. Cagnoni, and K. K. Iwata
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Mol. Cancer Ther., August 1, 2006; 5(8): 2051 - 2059.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. A. Engelman and L. C. Cantley
The Role of the ErbB Family Members in Non-Small Cell "Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors".
Clin. Cancer Res., July 15, 2006; 12(14): 4372s - 4376s.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Kalyankrishna and J. R. Grandis
Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2666 - 2672.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Van Schaeybroeck, J. Kyula, D. M. Kelly, A. Karaiskou-McCaul, S. A. Stokesberry, E. Van Cutsem, D. B. Longley, and P. G. Johnston
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1154 - 1165.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. Pino, M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey
Transforming Growth Factor {alpha} Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines.
Cancer Res., April 1, 2006; 66(7): 3802 - 3812.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. E. Konecny, M. D. Pegram, N. Venkatesan, R. Finn, G. Yang, M. Rahmeh, M. Untch, D. W. Rusnak, G. Spehar, R. J. Mullin, et al.
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Cancer Res., February 1, 2006; 66(3): 1630 - 1639.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. J. Friedmann, M. Caplin, B. Savic, T. Shah, C. J. Lord, A. Ashworth, J. A. Hartley, and D. Hochhauser
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Mol. Cancer Ther., February 1, 2006; 5(2): 209 - 218.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al.
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Clin. Cancer Res., December 15, 2005; 11(24): 8686 - 8698.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. J. Real, A. Benito, J. Cuevas, M. T. Berciano, A. de Juan, P. Coffer, J. Gomez-Roman, M. Lafarga, J. M. Lopez-Vega, and J. L. Fernandez-Luna
Blockade of Epidermal Growth Factor Receptors Chemosensitizes Breast Cancer Cells through Up-Regulation of Bnip3L
Cancer Res., September 15, 2005; 65(18): 8151 - 8157.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Jain, C. A. Tindell, I. Laux, J. B. Hunter, J. Curran, A. Galkin, D. E. Afar, N. Aronson, S. Shak, R. B. Natale, et al.
Epithelial membrane protein-1 is a biomarker of gefitinib resistance
PNAS, August 16, 2005; 102(33): 11858 - 11863.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, V. Guillem, S. Gonzalez, S. Sauleda, I. Marimon, J. M. Tabernero, et al.
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
J. Clin. Oncol., August 10, 2005; 23(23): 5323 - 5333.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. A. Burris III, H. I. Hurwitz, E. C. Dees, A. Dowlati, K. L. Blackwell, B. O'Neil, P. K. Marcom, M. J. Ellis, B. Overmoyer, S. F. Jones, et al.
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
J. Clin. Oncol., August 10, 2005; 23(23): 5305 - 5313.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, et al.
Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients
J. Clin. Oncol., August 1, 2005; 23(22): 5007 - 5018.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. J. Schilder, M. W. Sill, X. Chen, K. M. Darcy, S. L. Decesare, G. Lewandowski, R. B. Lee, C. A. Arciero, H. Wu, and A. K. Godwin
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Clin. Cancer Res., August 1, 2005; 11(15): 5539 - 5548.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, and J. DiGiovanni
Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5572 - 5580.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson
Development of strategies for the use of anti-growth factor treatments
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. A. Haas-Kogan, M. D. Prados, T. Tihan, D. A. Eberhard, N. Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, et al.
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
J Natl Cancer Inst, June 15, 2005; 97(12): 880 - 887.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N Normanno, A De Luca, D Aldinucci, M R Maiello, M Mancino, A D'Antonio, R De Filippi, and A Pinto
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis
Endocr. Relat. Cancer, June 1, 2005; 12(2): 471 - 482.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono
HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells
Cancer Res., May 15, 2005; 65(10): 4253 - 4260.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Jimeno, B. Rubio-Viqueira, M. L. Amador, D. Oppenheimer, N. Bouraoud, P. Kulesza, V. Sebastiani, A. Maitra, and M. Hidalgo
Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents
Cancer Res., April 15, 2005; 65(8): 3003 - 3010.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
K. M. Sheehan, V. S. Calvert, E. W. Kay, Y. Lu, D. Fishman, V. Espina, J. Aquino, R. Speer, R. Araujo, G. B. Mills, et al.
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
Mol. Cell. Proteomics, April 1, 2005; 4(4): 346 - 355.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. A. Engelman, P. A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson, and L. C. Cantley
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
PNAS, March 8, 2005; 102(10): 3788 - 3793.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. B. Solit, Y. She, J. Lobo, M. G. Kris, H. I. Scher, N. Rosen, and F. M. Sirotnak
Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel
Clin. Cancer Res., March 1, 2005; 11(5): 1983 - 1989.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. P. DiGiovanna, D. F. Stern, S. M. Edgerton, S. G. Whalen, D. Moore II, and A. D. Thor
Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients
J. Clin. Oncol., February 20, 2005; 23(6): 1152 - 1160.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Dai, Y.-H. Ling, M. Lia, Y.-Y. Zou, G. Kroog, K. K. Iwata, and R. Perez-Soler
Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines
Clin. Cancer Res., February 15, 2005; 11(4): 1572 - 1578.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Arao, H. Fukumoto, M. Takeda, T. Tamura, N. Saijo, and K. Nishio
Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474
Cancer Res., December 15, 2004; 64(24): 9101 - 9104.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. H. Kalish, R. A. Kwong, I. E. Cole, R. M. Gallagher, R. L. Sutherland, and E. A. Musgrove
Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines
Clin. Cancer Res., November 15, 2004; 10(22): 7764 - 7774.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. H. Kim, G. Ishii, K. Goto, K. Nagai, K. Tsuta, S. Shiono, J. Nitadori, T. Kodama, Y. Nishiwaki, and A. Ochiai
Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung
Clin. Cancer Res., November 1, 2004; 10(21): 7311 - 7317.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. E. Thompson and C. B. Thompson
Putting the Rap on Akt
J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. D. Britten
Targeting ErbB receptor signaling: A pan-ErbB approach to cancer
Mol. Cancer Ther., October 1, 2004; 3(10): 1335 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser
Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839)
Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, et al.
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting
Clin. Cancer Res., October 1, 2004; 10(19): 6487 - 6501.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Gregorc, G. L. Ceresoli, I. Floriani, A. Spreafico, K. B. Bencardino, V. Ludovini, L. Pistola, Z. Mihaylova, F. R. Tofanetti, M. Ferraldeschi, et al.
Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6006 - 6012.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Kuwahara, H. Hosoi, S. Osone, M. Kita, T. Iehara, H. Kuroda, and T. Sugimoto
Antitumor Activity of Gefitinib in Malignant Rhabdoid Tumor Cells In vitro and In vivo
Clin. Cancer Res., September 1, 2004; 10(17): 5940 - 5948.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, et al.
Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
J Natl Cancer Inst, August 4, 2004; 96(15): 1133 - 1141.
[Abstrac